Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy

Susanne Warner, Yu Hui Chang, Harshita Paripati, Helen J Ross, Jonathan Ashman, Kristi Harold, Ryan Day, Chee Chee Stucky, William Rule, Dawn Jaroszewski

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background Minimally invasive esophagectomy (MIE) is accepted for resection of early esophageal cancers. The optimal surgical approach for more advanced disease is unknown. An evaluation of MIE in patients with advanced tumors having undergone neoadjuvant chemoradiotherapy (nCRT) is presented. Methods A retrospective review of patients with esophageal cancer who underwent MIE from November 2006 to November 2011 was performed Results In total, 96 consecutive patients underwent MIE for malignancy. Median age was 65 years (range 26 to 88), and 86% were male. Adenocarcinoma represented 87% of patients. Eighty-three percent of patients were staged IIa or higher and 62 (65%) patients received neoadjuvant chemoradiotherapy. Four (6%) patients additionally received intraoperative electron beam radiotherapy. Twenty-six (27%) patients received postoperative adjuvant therapy with 22 (85%) of these having also received neoadjuvant chemoradiotherapy. All cases were completed thoraco-laparoscopically except for 2 conversions to mini-laparotomy. Twelve (12%) cervical anastomoses and 84 (88%) thoracic anastomoses were performed. Median operative time was 326 minutes (range 193 to 567) and did not differ significantly between those with and without nCRT. Complete pathologic response was seen in 21 (34%) of the 62 patients receiving neoadjuvant treatment. Major and minor morbidities were experienced in 28% and 38.5% of patients. There were 2 (2%) in-hospital mortalities; 1 each having received or not received neoadjuvant therapy. At median follow-up 24 months (range 3 to 70 months), overall survival was 58% and 55 (57%) patients were alive without recurrence. Conclusions Minimally invasive esophagectomy is an acceptable surgical therapy for advanced-stage esophageal malignancies after nCRT without evidence for increased morbidity or mortality.

Original languageEnglish (US)
Pages (from-to)439-445
Number of pages7
JournalAnnals of Thoracic Surgery
Volume97
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Esophagectomy
Chemoradiotherapy
Esophageal Neoplasms
Neoadjuvant Therapy
Morbidity
Neoplasms
Operative Time
Hospital Mortality
Laparotomy
Adenocarcinoma
Radiotherapy
Thorax
Electrons

Keywords

  • 7
  • CTSNet classification

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy. / Warner, Susanne; Chang, Yu Hui; Paripati, Harshita; Ross, Helen J; Ashman, Jonathan; Harold, Kristi; Day, Ryan; Stucky, Chee Chee; Rule, William; Jaroszewski, Dawn.

In: Annals of Thoracic Surgery, Vol. 97, No. 2, 02.2014, p. 439-445.

Research output: Contribution to journalArticle

Warner, Susanne ; Chang, Yu Hui ; Paripati, Harshita ; Ross, Helen J ; Ashman, Jonathan ; Harold, Kristi ; Day, Ryan ; Stucky, Chee Chee ; Rule, William ; Jaroszewski, Dawn. / Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy. In: Annals of Thoracic Surgery. 2014 ; Vol. 97, No. 2. pp. 439-445.
@article{657e911c8e024eb4a1586e707426831c,
title = "Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy",
abstract = "Background Minimally invasive esophagectomy (MIE) is accepted for resection of early esophageal cancers. The optimal surgical approach for more advanced disease is unknown. An evaluation of MIE in patients with advanced tumors having undergone neoadjuvant chemoradiotherapy (nCRT) is presented. Methods A retrospective review of patients with esophageal cancer who underwent MIE from November 2006 to November 2011 was performed Results In total, 96 consecutive patients underwent MIE for malignancy. Median age was 65 years (range 26 to 88), and 86{\%} were male. Adenocarcinoma represented 87{\%} of patients. Eighty-three percent of patients were staged IIa or higher and 62 (65{\%}) patients received neoadjuvant chemoradiotherapy. Four (6{\%}) patients additionally received intraoperative electron beam radiotherapy. Twenty-six (27{\%}) patients received postoperative adjuvant therapy with 22 (85{\%}) of these having also received neoadjuvant chemoradiotherapy. All cases were completed thoraco-laparoscopically except for 2 conversions to mini-laparotomy. Twelve (12{\%}) cervical anastomoses and 84 (88{\%}) thoracic anastomoses were performed. Median operative time was 326 minutes (range 193 to 567) and did not differ significantly between those with and without nCRT. Complete pathologic response was seen in 21 (34{\%}) of the 62 patients receiving neoadjuvant treatment. Major and minor morbidities were experienced in 28{\%} and 38.5{\%} of patients. There were 2 (2{\%}) in-hospital mortalities; 1 each having received or not received neoadjuvant therapy. At median follow-up 24 months (range 3 to 70 months), overall survival was 58{\%} and 55 (57{\%}) patients were alive without recurrence. Conclusions Minimally invasive esophagectomy is an acceptable surgical therapy for advanced-stage esophageal malignancies after nCRT without evidence for increased morbidity or mortality.",
keywords = "7, CTSNet classification",
author = "Susanne Warner and Chang, {Yu Hui} and Harshita Paripati and Ross, {Helen J} and Jonathan Ashman and Kristi Harold and Ryan Day and Stucky, {Chee Chee} and William Rule and Dawn Jaroszewski",
year = "2014",
month = "2",
doi = "10.1016/j.athoracsur.2013.09.042",
language = "English (US)",
volume = "97",
pages = "439--445",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy

AU - Warner, Susanne

AU - Chang, Yu Hui

AU - Paripati, Harshita

AU - Ross, Helen J

AU - Ashman, Jonathan

AU - Harold, Kristi

AU - Day, Ryan

AU - Stucky, Chee Chee

AU - Rule, William

AU - Jaroszewski, Dawn

PY - 2014/2

Y1 - 2014/2

N2 - Background Minimally invasive esophagectomy (MIE) is accepted for resection of early esophageal cancers. The optimal surgical approach for more advanced disease is unknown. An evaluation of MIE in patients with advanced tumors having undergone neoadjuvant chemoradiotherapy (nCRT) is presented. Methods A retrospective review of patients with esophageal cancer who underwent MIE from November 2006 to November 2011 was performed Results In total, 96 consecutive patients underwent MIE for malignancy. Median age was 65 years (range 26 to 88), and 86% were male. Adenocarcinoma represented 87% of patients. Eighty-three percent of patients were staged IIa or higher and 62 (65%) patients received neoadjuvant chemoradiotherapy. Four (6%) patients additionally received intraoperative electron beam radiotherapy. Twenty-six (27%) patients received postoperative adjuvant therapy with 22 (85%) of these having also received neoadjuvant chemoradiotherapy. All cases were completed thoraco-laparoscopically except for 2 conversions to mini-laparotomy. Twelve (12%) cervical anastomoses and 84 (88%) thoracic anastomoses were performed. Median operative time was 326 minutes (range 193 to 567) and did not differ significantly between those with and without nCRT. Complete pathologic response was seen in 21 (34%) of the 62 patients receiving neoadjuvant treatment. Major and minor morbidities were experienced in 28% and 38.5% of patients. There were 2 (2%) in-hospital mortalities; 1 each having received or not received neoadjuvant therapy. At median follow-up 24 months (range 3 to 70 months), overall survival was 58% and 55 (57%) patients were alive without recurrence. Conclusions Minimally invasive esophagectomy is an acceptable surgical therapy for advanced-stage esophageal malignancies after nCRT without evidence for increased morbidity or mortality.

AB - Background Minimally invasive esophagectomy (MIE) is accepted for resection of early esophageal cancers. The optimal surgical approach for more advanced disease is unknown. An evaluation of MIE in patients with advanced tumors having undergone neoadjuvant chemoradiotherapy (nCRT) is presented. Methods A retrospective review of patients with esophageal cancer who underwent MIE from November 2006 to November 2011 was performed Results In total, 96 consecutive patients underwent MIE for malignancy. Median age was 65 years (range 26 to 88), and 86% were male. Adenocarcinoma represented 87% of patients. Eighty-three percent of patients were staged IIa or higher and 62 (65%) patients received neoadjuvant chemoradiotherapy. Four (6%) patients additionally received intraoperative electron beam radiotherapy. Twenty-six (27%) patients received postoperative adjuvant therapy with 22 (85%) of these having also received neoadjuvant chemoradiotherapy. All cases were completed thoraco-laparoscopically except for 2 conversions to mini-laparotomy. Twelve (12%) cervical anastomoses and 84 (88%) thoracic anastomoses were performed. Median operative time was 326 minutes (range 193 to 567) and did not differ significantly between those with and without nCRT. Complete pathologic response was seen in 21 (34%) of the 62 patients receiving neoadjuvant treatment. Major and minor morbidities were experienced in 28% and 38.5% of patients. There were 2 (2%) in-hospital mortalities; 1 each having received or not received neoadjuvant therapy. At median follow-up 24 months (range 3 to 70 months), overall survival was 58% and 55 (57%) patients were alive without recurrence. Conclusions Minimally invasive esophagectomy is an acceptable surgical therapy for advanced-stage esophageal malignancies after nCRT without evidence for increased morbidity or mortality.

KW - 7

KW - CTSNet classification

UR - http://www.scopus.com/inward/record.url?scp=84895068586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895068586&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2013.09.042

DO - 10.1016/j.athoracsur.2013.09.042

M3 - Article

C2 - 24266955

AN - SCOPUS:84895068586

VL - 97

SP - 439

EP - 445

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 2

ER -